AOTI INC (AOTI) — Results for the year ended 31 December 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the AOTI INC results presentation. Throughout today's recorded meeting, attendees will be in listen only mode. Questions are encouraged. They can be submitted at any time just using the Q and A tab situated on the right hand corner of your screen. Please simply type in your questions at any time and press send. Before we begin, we'd like to submit the following poll, and I'm sure the company would be most grateful for your participation. I'd now like to hand over to the management team, Mike, Jayesh. Good afternoon. Good afternoon, everyone. Welcome, everybody, and we're gonna walk through our results presentation. You got myself here, Mike Griffith, CEO, and our CFO, Jash Pankarnieth here. Okay. Little summary of who we are. You know, we're a company focused on both saving limbs and indirectly saving the lives of patients by healing their chronic wounds more durably. And our overall mission is to really help people with chronic disease get back to living their lives to the fullest. We're a strong, value driven company, and we're able, you know, our market is defined by our leading, unique topical induction therapy, is proven to heal hard to heal wounds more effectively. The investment case, we believe, is strong and compelling. The hard to heal wound market is significant. We'll give you some ideas of the song and sound in a little bit. We have an established product with very strong clinical evidence. It's demonstrated better hearing with lower recurrence, so there's significant clinical, also cost saving for payers. The company had organic growth in in '25 of over $66,000,000 and positive cash flow and EBITDA. We're a clear business model for expansion and significant future growth as broader coverage comes down...